Taking Aim at an Ideal Therapeutic Target in Relapsed/Refractory Multiple Myeloma

Please Log In or Register to continue.

Release Date: August 27, 2020
Expiration Date: August 27, 2021

Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.

This activity was previously presented between August 10 and 17, 2020 as a live webinar. Please note: If you participated in one of the live webinars, you are ineligible to receive an additional 1.0 contact hour of credit and may not re-submit for credit previously awarded.

Program Overview

Awareness and knowledge of B-cell maturation antigen (BCMA) as a therapeutic target remains limited among clinicians who provide care for patients with relapsed/refractory multiple myeloma (MM). However, the number of clinical trials evaluating these therapies is rapidly increasing; and a few have even received breakthrough therapy status. In this activity, three experts provide a better understanding of BCMA as a target, along with an improved knowledge of emerging efficacy and safety data that may soon inform the use of these promising strategies in clinical practice.

Target Audience

This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, nurses, pharmacists and other allied healthcare professionals who provide care to patients with multiple myeloma.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Explain the importance of BCMA as a therapeutic target in multiple myeloma, as shown in studies of antibody-drug conjugates, T-cell based therapy, and other approaches
  • Integrate BCMA-directed therapy into clinical practice for patients with multiple myeloma
  • Develop patient monitoring and management strategies for the toxicities associated with BCMA-targeted therapies

Agenda

Targeting BCMA in Myeloma: Where Are We Now and Where Are We Going? – Sarah A. Holstein, MD, PhD

The Efficacy of BCMA-directed Therapy in Myeloma: What Do We Know? – Muhamed Baljevic, MD

TEAEs Related to BCMA-directed Therapy: What to Expect, and How to Manage Them – Natalie S. Callander, MD

BCMA-directed Therapies: What Do We Know About Resistance Mechanisms and Sequencing? – Sarah A. Holstein, MD, PhD

Instructions for Participation and Credit

This activity is eligible for credit through August 27, 2021. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME and CE may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biographies

Sarah A. Holstein, MD, PhD
Associate Professor
Division of Oncology and Hematology
Department of Internal Medicine
University of Nebraska Medical Center
Omaha, Nebraska

Dr. Sarah Holstein received her medical degree and PhD in pharmacology from the University of Iowa Carver College of Medicine. She continued her postgraduate studies there with a residency in internal medicine and a fellowship in hematology/oncology. She is currently an Associate Professor in the Division of Oncology and Hematology, Department of Internal Medicine, at the University of Nebraska Medical Center in Omaha.

Dr. Holstein holds board certification in internal medicine, hematology, oncology, as well as by the National Board of Physicians and Surgeons. She is a member of the American College of Physicians, American Society of Hematology, American Society of Clinical Oncology, American Society for Clinical Pharmacology and Therapeutics, and the International Myeloma Society of Hematologic Oncology. In addition, Dr. Holstein is a member of the Alliance Multiple Myeloma Committee and the NCCN Multiple Myeloma Panel. She has written numerous peer-reviewed research articles as well as review articles and book chapters, and is an ad hoc reviewer for dozens of peer-review journals.

As a physician-scientist who specializes in the treatment of multiple myeloma, Dr. Holstein’s laboratory is focused on gaining a better understanding of the pathophysiology and the development of novel therapeutic agents for this disease. She is an active clinical investigator, and has been involved in clinical trials for newly diagnosed myeloma, relapsed/refractory disease, as well as in the post-transplant maintenance setting.

Muhamed Baljevic, MD
Assistant Professor of Medicine
Division of Hematology and Oncology
Department of Internal Medicine
University of Nebraska Medical Center
Omaha, Nebraska

Dr. Muhamed Baljevic completed his medical education at the Weill Cornell Medical College. During his medical training, he worked in the Ansary Center for Stem Cell Therapeutics at the Weill Cornell Medical College of Cornell University. He subsequently completed his internal medicine internship and residency at New York-Presbyterian Hospital Weill Cornell Medical Center, and his hematology and medical oncology training at The University of Texas MD Anderson Cancer Center. In addition, Dr. Baljevic pursued a master’s degree in clinical and translational research at The University of Texas Graduate School of Biomedical Sciences. Dr. Baljevic is Assistant Professor of Medicine in the Division of Hematology and Oncology, Department of Internal Medicine at the University of Nebraska Medical Center (UNMC), where he also works as a plasma cell dyscrasia (PCD) specialist, transplanter, and clinical/translational trialist at Fred & Pamela Buffet Cancer Center (FPBCC).

Dr. Baljevic is a member of the American Society of Clinical Oncology (ASCO), the American Society of Hematology, the American Association for Cancer Research (AACR), the European Hematology Association, and the American Society of Transplantation and Cellular Therapy. In addition, he is a member of the NCCN Multiple Myeloma/Systemic Light Chain Amyloidosis/Waldenström's Macroglobulinemia Panel, as well as the Myeloma CAR T cell strategic council. Dr. Baljevic serves on the editorial board for Frontiers in Oncology. He also has contributed to publications in Nature Medicine, Cancer Cell, Journal of Clinical Investigation, Circulation Research, Hematology/Oncology Clinics of North America, as well as several book chapters.

In his current role at FPBCC, Dr. Baljevic investigates early-phase development of pre-clinical concepts in post-transplant immune reconstitution in an effort to obtain a better understanding of proteasome inhibitor resistance. His research also seeks to identify novel approaches for the treatment of B-cell and myeloid malignancies, including novel immunotherapy, antibody conjugates, CAR T cells, BiTEs, and small molecule targeted inhibitors. He recently successfully performed the first bloodless stem cell transplantation for a Jehovah’s Witness multiple myeloma patient in the state of Nebraska.

Natalie S. Callander, MD
Professor of Medicine
Department of Hematology/Bone Marrow Transplant
University of Wisconsin School of Medicine and Public Health
Madison, Wisconsin

Dr. Natalie Callander received her medical degree from Tufts University School of Medicine, Boston. She completed her residency and internship at Bellevue Hospital in New York City, and her fellowship at the University of California San Diego Medical Center. Dr. Callander is a Professor of Medicine in the Department of Hematology/Bone Marrow Transplant at the University of Wisconsin. In addition, she is an Attending Physician at the William S. Middleton Memorial Veterans Hospital and Director of the Myeloma Clinical Program.

Dr. Callander is board certified in hematology, internal medicine, and medical oncology. She holds memberships in the American Society of Hematology, American Society of Clinical Oncology, American Society of Bone Marrow Transplantation, the Eastern Cooperative Oncology Group, and the National Comprehensive Cancer Network, among others. In addition, she is an ad hoc reviewer for publications including Blood, Blood and Bone Marrow Transplantation, British Medical Journal, and the American Journal of Hematology. Dr. Callander’s clinical and research interests include inpatient and outpatient care of hematology and bone marrow transplant patients and multiple myeloma.

Accreditation

University of Nebraska Medical Center CME Credit
The University of Nebraska Medical Center, Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Nebraska Medical Center, Center for Continuing Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  Nursing Credit
The University of Nebraska Medical Center College of Nursing Continuing Nursing Education is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. This activity is provided for 1.0 contact hour under ANCC criteria. Program #: 20CC126E

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Nurses Credentialing Center’s Commission on Accreditation (ANCC) through the joint providership of the University of Nebraska Medical Center College of Nursing Continuing Nursing Education (UNMC CON CNE) (provider) and University of Nebraska Medical Center, Center for Continuing Education (UNMC CCE).
MediCom Worldwide, Inc. CPE Credit
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-20-034-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.

International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.

Disclosure
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME) and American Nurses Credentialing Center (ANCC), University of Nebraska Medical Center, Center for Continuing Education and University of Nebraska Medical Center, College of Nursing Continuing Nursing Education and as an organization accredited by the Accreditation Council for Pharmacy Education (ACPE), MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosures

Dr. Sarah Holstein has received honoraria related to formal advisory activities and as a consultant from Celgene Corporation – A Bristol-Myers Squibb Company, Genentech, GlaxoSmithKline plc, Inc. Oncopeptides, AB, and Sanofi.

Dr. Muhamed Baljevic has received honoraria related to formal advisory activities and as a consultant from Bristol-Myers Squibb Company and Celgene Corporation – A Bristol-Myers Squibb Company. He has received grant support related to research activities from Karyopharm Therapeutics.

Dr. Natalie Callander has received honoraria as a consultant from Cellectar Biosciences, Inc.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, Isabelle Vacher, Vice President of Educational Strategy, Wilma Guerra, Program Director, and Andrea Mathis, Project Manager, have no relevant financial relationships.

The individuals listed below from the University of Nebraska Medical Center reported the following for this activity: Brenda Ram, CMP, CHCP, Director, Educational Programs, UNMC Center for Continuing Education, Heidi Keeler, PhD, RN, Lead Nurse Planner/Director and Renee Paulin, MSN, RN, CWOCN, Nurse Planner, UNMC College of Nursing Continuing Nursing Education, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

If you have any questions, please contact MediCom Worldwide, Inc. at 800-408-4242, or cmettille@medicaled.com.

Provided by University of Nebraska Medical Center and MediCom Worldwide, Inc.
This activity is supported by an educational grant from GlaxoSmithKline.

©2020 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

Please Log In or Register to continue.